Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia

International Journal of Hematologic Oncology

Mesut Gocer¹  Engin Kelkitli¹  Fahri Sahin²  Nur Soyer²  Sirac Bozkurt³  Birkan Aver⁴  Egemen Ozbilgili⁵  Osman Ilhan⁵  Begum Ozdengulsun⁵  Guray Saydam⁶  Mehmet Yilmaz⁶  Meliha Nalcaci⁶  Ali Unal⁷  Ibrahim Celalettin Haznedaroglu⁸  Abdullah Hacihanifioglu⁹  Ozgur Mehtap⁹  Erdal Kurtoglu^1,10  Mehmet Turgut^1,10  Memis Hilmi Atay^1,11  Basak Unver Koluman^1,11  Nil Guler^1,11  Nergiz Erkut^1,12  Mehmet Sonmez^1,12  Emin Kaya^1,13  Irfan Kuku^1,13  Gulsum Ozet^1,14  Funda Ceran^1,14  Mehmet Ali Erkurt^1,14 

[1] Research Hospital, Antalya, 07100, Turkey;10Department of Hematology, Ankara City Hospital, Ankara, 06800, Turkey;12Department of Internal Diseases, Istanbul University Istanbul Faculty of Medicine, Istanbul, 34093, Turkey;13Department of Internal Diseases, Division of Hematology, SANKO University Faculty of Medicine, Gaziantep, 27090, Turkey;14Department of Medical Oncology, Pfizer Pharmaceuticals, Istanbul, 34394, Turkey;1Department of Internal Diseases, Division of Hematology, Ege University Medical Faculty Hospital, Izmir, 35100, Turkey;2Department of Internal Diseases, Division of Hematology, Erciyes University Faculty of Medicine, Kayseri, 38030, Turkey;3Department of Internal Diseases, Division of Hematology, Hacettepe University Faculty of Medicine, Ankara, 06230, Turkey;4Department of Internal Diseases, Division of Hematology, Kocaeli University Faculty of Medicine, Izmit, 41001, Turkey;;5Department of Internal Diseases, Division of Hematology, University of Health Sciences, Antalya Training &6Department of Internal Diseases, Division of Hematology, Ondokuz Mayis University Faculty of Medicine, Samsun, 55139, Turkey;7Department of Internal Diseases, Pamukkale University Faculty of Medicine, Denizli, 20160, Turkey;8Department of Internal Diseases, Division of Hematology, Karadeniz Technical University Faculty of Medicine, Trabzon, 61080, Turkey;9Department of Internal Diseases, Division of Hematology, Inonu University Faculty of Medicine, Malatya, 44280, Turkey;

关键词: chronic myeloid leukemia;    co-medication use;    comorbidity;    cytogenetic response;    hematologic response;    molecular response;   

DOI  :  10.2217/ijh-2021-0008

来源: DOAJ

【 摘 要 】

Aim: This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey. Materials & methods: Hospital records between 2005 and 2018 were retrospectively reviewed. Results: Of 861 CP-CML patients included, 31% had at least one comorbidity at diagnosis. Sex, cardiovascular disease status at diagnosis and molecular (at least major) and cytogenetic (partial and complete) responses were the independent predictors of survival. Conclusion: The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients.

【 授权许可】

Unknown